Browsing by Author "Kutlu M."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    The prevalence of microalbuminuria and relevant cardiovascular risk factors in Turkish hypertensive patients
    (2011) Kozan Ö.; Özcan E.E.; Sancaktar O.; Kabakci G.; Sözcüer A.H.; Kerpeten A.; Delice A.; Içli A.; Sökmen A.; Gürlek A.; Abaci A.; Bayram A.; Köşüş A.; Çamsari A.; Sakalli A.; Sert A.; Temizhan A.; Yilmaz A.; Daver A.; Aydinlar A.; Ergin A.; Kiliçoǧlu A.E.; Birdane A.; Aribaş A.; Lazoǧlu A.; Özdemir A.; Fiskeci A.; Çelik A.; Bitigen A.; Keskin A.; Yavuz A.; Akyüz A.; Karanfil A.; Ünsal A.; Sinci A.; Gülmez A.U.; Irmak A.; Vural A.; Güven A.; Ilerigelen B.; Erol B.; Polat B.; Tosun B.; Aǧçal C.; Genç C.; Kirdar C.; Rezzagil C.; Köz C.; Nazli C.; Ceyhan C.; Örem C.; Uyan C.; Türkoǧlu C.; Gaffari D.; Aytekin D.; Ural D.; Yeşilbursa D.; Aras D.; Semiz E.; Koçak E.; Atalar E.; Varol E.; Onrat E.; Şensoy E.; Acartürk E.; Akarca E.; Aygün E.; Ertaş F.S.; Koca F.; Özmen F.; Ulusoy F.V.; Özerkan F.; Inceer F.K.; Dönmez G.; Topkara G.; Daş G.; Bozkurt H.; Kültürsay H.; Tikiz H.; Akgöz H.; Kaymak H.; Öney H.; Yeǧin H.; Boǧa H.; Gök H.; Vural H.; Atasever H.; Arinç H.; Bozdemir H.; Gündüz H.; Tunar H.; Atmaca H.; Doǧru I.; Özdoǧru I.; Susal I.; Kurt I.T.; Dinçer I.; Biyik I.; Tandoǧan I.; Jordan J.; Kulan K.; Şahna K.; Öztaş K.; Dönmez K.; Övünç K.; Kaya K.; Aytemir K.; Özdemir K.; Tigen K.; Saraç L.; Sirkeci M.T.; Çakmak M.; Şahin M.; Kutlu M.; Bilge M.; Bostan M.; Melek M.; Sunay M.Ö.; Şeker M.; Güçel M.Ş.; Yazici M.; Kayikçioǧlu M.; Öç M.; Gürsürer M.; Daǧalp M.; Bilaloǧlu M.; Yalçin M.; Şerifi M.; Gökçe M.; Kiliçkap M.; Polat M.; Şan M.; Tahtasiz M.; Yilmaz M.; Etemoǧlu M.; Coşkun N.; Aran N.S.; Ata N.; Sönmez N.; Çam N.; Koylan N.; Özer N.; Keser N.; Döven O.; Tartanoǧlu O.; Ergene O.; Elönü O.H.; Onbaşili O.A.; Özbek Ö.; Pinar P.; Akdemir R.; Kargin R.; Topsakal R.; Yoldaş R.; Uçar R.; Ateşal S.; Toktaş S.; Cinsoy S.; Güleç S.; Aytekin S.; Çolak S.; Mecit S.; Sakalli S.; Sevimli S.; Topaloǧlu S.; Aydoǧdu S.; Turan S.C.; Kahraman S.; Yorganci S.; Coşkun Ş.; Ünal Ş.; Durmaz T.; Ulusoy T.; Keleş T.; Kirat T.; Gündoǧdu T.T.; Peker T.; Sümerkan U.; Aytekin V.; Koca V.; Çam V.; Gökçe V.; Gürlertop Y.; Balbay Y.; Çavuşoǧlu Y.; Erzurum Y.; Selçoki Y.; Yakar Y.; Işilak Z.; Tosun Z.; Kaplan Z.; Tartan Z.
    Objectives: A growing body of data illustrates the importance of microalbuminuria (MAU) as a strong predictor of cardiovascular risk in the hypertensive population. The present study was designed to define the prevalence of MAU and associated cardiovascular risk factors among Turkish hypertensive outpatients. Study design: Representing the Turkish arm of the multinational i-SEARCH study involving 1,750 sites in 26 countries around the world, a total of 1,926 hypertensive patients from different centers were included in this observational and cross-sectional survey study. Patients with reasons for a false-positive MAU test were excluded. The prevalence of MAU was assessed using a dipstick test, and patients were inquired about comorbidities, comedication, and known cardiovascular risk factors. Results: The overall prevalence of MAU was 64.7% and there was no difference between genders. Most of the patients (82.5%) had uncontrolled hypertension, 35.6% had dyslipidemia, and 35.5% had diabetes, predominantly type 2. Almost one-third of the patients (26.4%) had at least one cardiovascular-related comorbidity, with 20.3% having documented coronary artery disease (CAD). Almost all patients (96.8%) had one or more risk factors for cardiovascular disease in addition to hypertension, including family history of myocardial infarction or CAD, diabetes, dyslipidemia, lack of physical exercise, and smoking. A trend towards higher MAU values in the presence of CAD was determined. Conclusion: Microalbuminuria tests should be routinely used as a screening and monitoring tool for the assessment of subsequent cardiovascular morbidity and mortality among hypertensive patients. © 2011 Turkish Society of Cardiology.
  • No Thumbnail Available
    Item
    Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study)
    (Elsevier Ireland Ltd, 2018) Sonmez A.; Haymana C.; Bayram F.; Salman S.; Dizdar O.S.; Gurkan E.; Kargili Carlıoglu A.; Barcin C.; Sabuncu T.; Satman I.; Guldiken S.; Ayturk S.; Yilmaz M.; Asik M.; Dinccag N.; Cakmak R.; Turker F.; Idiz C.; Hacisahinogullari H.; Bagdemir E.; Yildiz B.; Yumuk V.D.; Haliloglu O.; Sancak S.; Ozsari L.; Cagiltay E.; Deyneli O.; Imre E.; Gonen S.; Boysan S.N.; Altuntas Y.; Ozturk F.Y.; Mert M.; Piskinpasa H.; Aydin H.; Imamoglu S.; Ersoy C.; Gul O.O.; Kucuksarac Kiyici S.; Cetinarslan B.; Selek A.; Dogru T.; Kirik A.; Kebapci N.; Efe B.; Kaya A.; Cordan I.; Baldane S.; Kirac C.O.; Demirci I.; Capa Z.; Cesur M.; Yetkin I.; Corapcioglu D.; Canlar S.; Bulent Yildiz O.; Sendur S.N.; Cakir B.; Ozdemir D.; Corakci A.; Kutlu M.; Bascil Tutuncu N.; Bozkus Y.; Cakal E.; Demirbas B.; Ertek S.; Altay M.; Dagdeviren M.; Abedi A.H.; Cetinkalp S.; Ozisik H.; Oruk G.G.; Yener S.; Saydam B.O.; Guney E.; Unubol M.; Yaylali G.F.; Topsakal S.; Hekimsoy Z.; Akbaba G.; Aslan I.; Balci M.K.; Dalkiran S.; Akbay E.; Gul K.; Agbaht K.; Yilmaz M.O.; Bozkirli E.; Tetiker B.T.; Cetinkaya Altuntas S.; Atmaca A.; Durmuş E.T.; Mete T.; Kutluturk F.; Kucukler F.K.; Dikbas O.; Akin S.; Nuhoglu I.; Ersoz H.O.; Bayraktaroglu T.; Sisman P.; Sahin I.; Cetin S.; Capoglu I.; Akbas E.M.; Ucler R.; Eren M.A.; Tuzcu A.K.; Pekkolay Z.; Ozkaya M.; Araz M.
    Aims: Turkey has the highest prevalence of diabetes in Europe. It is therefore essential to know the overall cardiovascular risk and reveal the predictors of metabolic control in Turkish adults with diabetes mellitus. Methods: A nationwide, multicenter survey consecutively enrolled patients who were under follow up for at least a year. Optimal control was defined as HbA1c < 7%, home arterial blood pressure (ABP) < 135/85 mmHg, or LDL-C < 100 mg/dL. Achieving all parameters indicated triple metabolic control. Results: HbA1c levels of patients (n = 5211) were 8.6 ± 1.9% (71 ± 22 mmol/mol) and 7.7 ± 1.7% (61 ± 19 mmol/mol), in Type 1 and Type 2 diabetes, respectively. Glycemic control was achieved in 15.3% and 40.2%, and triple metabolic control was achieved in 5.5% and 10.1%, respectively. Only 1.5% of patients met all the criteria of being non-obese, non-smoker, exercising, and under triple metabolic control. Low education level was a significant predictor of poor glycemic control in both groups. Conclusions: Few patients with Type 2, and even fewer with Type 1 diabetes have optimal metabolic control in Turkey. TEMD study will provide evidence-based information to policy makers to focus more on the quality and sustainability of diabetes care in order to reduce the national burden of the disease. © 2018 Elsevier B.V.
  • No Thumbnail Available
    Item
    Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study)
    (BioMed Central Ltd, 2020) Bayram F.; Sonmez A.; Haymana C.; Sabuncu T.; Dizdar O.S.; Gurkan E.; Carlioglu A.K.; Agbaht K.; Ozdemir D.; Demirci I.; Barcin C.; Salman S.; Tetiker T.; Balci M.K.; Kebapci N.; Ersoy C.; Yumuk V.; Toth P.P.; Satman I.; Guldiken S.; Ayturk S.; Yilmaz M.; Asik M.; Dinccag N.; Cakmak R.; Turker F.; Idiz C.; Hacisahinogullari H.; Bagdemir E.; Yildiz B.; Haliloglu O.; Sancak S.; Ozsari L.; Cagiltay E.; Deyneli O.; Imre E.; Gonen S.; Boysan S.N.; Altuntas Y.; Ozturk F.Y.; Mert M.; Piskinpasa H.; Aydin H.; Imamoglu S.; Gul O.O.; Kiyici S.K.; Cetinarslan B.; Selek A.; Dogru T.; Kirik A.; Efe B.; Kaya A.; Cordan I.; Baldane S.; Kirac C.O.; Capa Z.; Cesur M.; Yetkin I.; Corapcioglu D.; Canlar S.; Yildiz O.B.; Sendur S.N.; Cakir B.; Corakci A.; Kutlu M.; Tutuncu N.B.; Bozkus Y.; Cakal E.; Demirbas B.; Ertek S.; Altay M.; Dagdeviren M.; Abedi A.H.; Cetinkalp S.; Ozisik H.; Oruk G.G.; Yener S.; Saydam B.O.; Guney E.; Unubol M.; Yaylali G.F.; Topsakal S.; Hekimsoy Z.; Akbaba G.; Aslan I.; Dalkiran S.; Akbay E.; Gul K.; Yilmaz M.O.; Bozkirli E.; Altuntas S.C.; Atmaca A.; Durmuş E.T.; Mete T.; Kutluturk F.; Kucukler F.K.; Dikbas O.; Akin S.; Nuhoglu I.; Ersoz H.O.; Bayraktaroglu T.; Sisman P.; Sahin I.; Cetin S.; Capoglu I.; Akbas E.M.; Ucler R.; Eren M.A.; Tuzcu A.K.; Pekkolay Z.; Ozkaya M.; Araz M.
    Background: Attaining acceptable levels of LDL Cholesterol (LDL-C) significantly improves cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM). The LDL-C target attainment and the characteristics of patients attaining these targets were investigated in this study. Furthermore, the reasons for not choosing statins and the physicians’ attitudes on the treatment of diabetic dyslipidemia were also examined. Methods: A nationwide, cross-sectional survey was conducted in tertiary centers for diabetes management. Adult patients with T2DM, who were under follow-up for at least a year in outpatient clinics, were consecutively enrolled for the study. LDL-C goals were defined as below 70 mg/dL for patients with macrovascular complications or diabetic nephropathy, and below 100 mg/dL for other patients. Data about lipid-lowering medications were self-reported. Results: A total of 4504 patients (female: 58.6%) were enrolled for the study. The mean HbA1c and diabetes duration was 7.73 ± 1.74% and 10.9 ± 7.5 years, respectively. The need for statin treatment was 94.9% (n = 4262); however, only 42.4% (n = 1807) of these patients were under treatment, and only 24.8% (n = 448) of these patients achieved LDL-C targets. The main reason for statin discontinuation was negative media coverage (87.5%), while only a minority of patients (12.5%) mentioned side effects. Physicians initiated lipid-lowering therapy in only 20.3% of patients with high LDL-C levels. It was observed that the female gender was a significant independent predictor of not attaining LDL-C goals (OR: 0.70, 95% CI: 0.59–0.83). Conclusions: Less than 50 % of patients with T2DM who need statins were under treatment, and only a quarter of them attained their LDL-C targets. There exists a significant gap between the guideline recommendations and the real-world evidence in the treatment of dyslipidemia in T2DM. © 2020, The Author(s).
  • No Thumbnail Available
    Item
    Mortality-associated factors of candidemia: a multi-center prospective cohort in Turkey
    (Springer Science and Business Media Deutschland GmbH, 2022) Kutlu M.; Sayın-Kutlu S.; Alp-Çavuş S.; Öztürk Ş.B.; Taşbakan M.; Özhak B.; Kaya O.; Kutsoylu O.E.; Şenol-Akar Ş.; Turhan Ö.; Mermut G.; Ertuğrul B.; Pullukcu H.; Çetin Ç.B.; Avkan-Oğuz V.; Yapar N.; Yeşim-Metin D.; Ergin Ç.
    Candidemia may present as severe and life-threatening infections and is associated with a high mortality rate. This study aimed to evaluate the risk factors associated with 30-day mortality in patients with candidemia. A multi-center prospective observational study was conducted in seven university hospitals in six provinces in the western part of Turkey. Patient data were collected with a structured form between January 2018 and April 2019. In total, 425 episodes of candidemia were observed during the study period. Two hundred forty-one patients died within 30 days, and the 30-day crude mortality rate was 56.7%. Multivariable analysis found that SOFA score (OR: 1.28, CI: 1.154–1.420, p < 0.001), parenteral nutrition (OR: 3.9, CI: 1.752–8.810, p = 0.001), previous antibacterial treatment (OR: 9.32, CI: 1.634–53.744, p = 0.012), newly developed renal failure after candidemia (OR: 2.7, CI: 1.079–6.761, p = 0.034), and newly developed thrombocytopenia after candidemia (OR: 2.6, CI: 1. 057–6.439, p = 0.038) were significantly associated with 30-day mortality. Central venous catheter removal was the only factor protective against mortality (OR: 0.34, CI:0.147–0.768, p = 0.010) in multivariable analysis. Candidemia mortality is high in patients with high SOFA scores, those receiving TPN therapy, and those who previously received antibacterial therapy. Renal failure and thrombocytopenia developing after candidemia should be followed carefully in patients. Antifungal therapy and removing the central venous catheter are essential in the management of candidemia. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.